Honey
( DrugBank: Honey / KEGG DRUG: Honey )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 57 | Idiopathic dilated cardiomyopathy | 1 |
| 63 | Idiopathic thrombocytopenic purpura | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastro-intestinal disorder | 1 |
| 230 | Alveolar hypoventilation syndrome | 1 |
57. Idiopathic dilated cardiomyopathy
Clinical trials : 148 / Drugs : 217 - (DrugBank : 60) / Drug target genes : 46 - Drug target pathways : 143
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. Idiopathic thrombocytopenic purpura
Clinical trials : 868 / Drugs : 544 - (DrugBank : 96) / Drug target genes : 82 - Drug target pathways : 195
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
98. Eosinophilic gastro-intestinal disorder
Clinical trials : 222 / Drugs : 226 - (DrugBank : 48) / Drug target genes : 48 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
230. Alveolar hypoventilation syndrome
Clinical trials : 13 / Drugs : 25 - (DrugBank : 7) / Drug target genes : 16 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|